Pan Jianwei, Fan Weijian, Gu Chenjie, Xi Yongmei, Wang Yu, Wang Peter
Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Institute of Genetic, Zhejiang University, Hangzhou 310007, China.
Genes (Basel). 2024 Dec 18;15(12):1620. doi: 10.3390/genes15121620.
Ischemic stroke is a serious cerebrovascular disease, highlighting the urgent need for reliable biomarkers for early diagnosis. Recent reports suggest that long non-coding RNAs (lncRNAs) can be potential biomarkers for ischemic stroke. Therefore, our study seeks to investigate the potential diagnostic value of lncRNAs for ischemic stroke by analyzing existing research. A comprehensive literature search was conducted across the PubMed, ScienceDirect, Wiley Online Library, and Web of Science databases for articles published up to July 10, 2024. Statistical analyses were performed using Stata 17.0 software to calculate pooled sensitivity, specificity, positive likelihood ratio (PLR), diagnostic odds ratio (DOR), negative likelihood ratio (NLR), and area under the curve (AUC). Heterogeneity was explored with the Cochran-Q test and the I statistical test, and publication bias was assessed with Deeks' funnel plot. A total of 44 articles were included, involving 4302 ischemic stroke patients and 3725 healthy controls. Results demonstrated that lncRNAs H19, GAS5, PVT1, TUG1, and MALAT1 exhibited consistent trends across multiple studies. The pooled sensitivity of lncRNAs in the diagnosis of ischemic stroke was 79% (95% CI: 73-84%), specificity was 88% (95% CI: 77-94%), PLR was 6.63 (95% CI: 3.11-14.15), NLR was 0.23 (95% CI: 0.16-0.33), DOR was 28.5 (95% CI: 9.88-82.21), and AUC was 0.88 (95% CI: 0.85-0.90). Furthermore, the results of subgroup analysis indicated that lncRNA H19 had superior diagnostic performance. LncRNAs demonstrated strong diagnostic accuracy in distinguishing ischemic stroke patients from healthy controls, underscoring their potential as reliable biomarkers. Because most of the articles included in this study originate from China, large-scale, high-quality, multi-country prospective studies are required to further validate the reliability of lncRNAs as biomarkers for ischemic stroke.
缺血性中风是一种严重的脑血管疾病，凸显了对用于早期诊断的可靠生物标志物的迫切需求。最近的报告表明，长链非编码RNA（lncRNAs）可能是缺血性中风的潜在生物标志物。因此，我们的研究旨在通过分析现有研究来探讨lncRNAs对缺血性中风的潜在诊断价值。我们在PubMed、ScienceDirect、Wiley Online Library和Web of Science数据库中进行了全面的文献检索，以查找截至2024年7月10日发表的文章。使用Stata 17.0软件进行统计分析，以计算合并敏感度、特异度、阳性似然比（PLR）、诊断比值比（DOR）、阴性似然比（NLR）和曲线下面积（AUC）。使用Cochran-Q检验和I统计检验探讨异质性，并使用Deeks漏斗图评估发表偏倚。总共纳入了44篇文章，涉及4302例缺血性中风患者和3725例健康对照。结果表明，lncRNAs H19、GAS5、PVT1、TUG1和MALAT1在多项研究中呈现出一致的趋势。lncRNAs在缺血性中风诊断中的合并敏感度为79%（95%CI：73-84%），特异度为88%（95%CI：77-94%），PLR为6.63（95%CI：3.11-14.15），NLR为0.23（95%CI：0.16-0.33），DOR为28.5（95%CI：9.88-82.21），AUC为0.88（95%CI：0.85-0.90）。此外，亚组分析结果表明lncRNA H19具有卓越的诊断性能。LncRNAs在区分缺血性中风患者和健康对照方面显示出强大的诊断准确性，突出了它们作为可靠生物标志物的潜力。由于本研究纳入的大多数文章来自中国，因此需要进行大规模、高质量、多国前瞻性研究，以进一步验证lncRNAs作为缺血性中风生物标志物的可靠性。
